AngioDynamics (NASDAQ:ANGO) Posts Quarterly Earnings Results, Beats Estimates By $0.03 EPS

AngioDynamics (NASDAQ:ANGO) announced its quarterly earnings results on Wednesday. The medical instruments supplier reported $0.01 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.02) by $0.03, MarketWatch Earnings reports. The firm had revenue of $72.80 million during the quarter, compared to the consensus estimate of $67.33 million. AngioDynamics had a positive return on equity of 0.18% and a negative net margin of 62.90%. The firm’s quarterly revenue was up 4.0% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.06 EPS.

ANGO traded up $0.58 during trading hours on Friday, hitting $19.15. 5,128 shares of the company’s stock were exchanged, compared to its average volume of 240,508. AngioDynamics has a 1-year low of $7.48 and a 1-year high of $19.52. The stock’s 50-day moving average is $14.29 and its two-hundred day moving average is $11.16. The stock has a market cap of $726.74 million, a price-to-earnings ratio of -4.37 and a beta of 0.89. The company has a quick ratio of 2.25, a current ratio of 3.57 and a debt-to-equity ratio of 0.09.

ANGO has been the topic of a number of recent research reports. Raymond James raised their target price on shares of AngioDynamics from $18.00 to $24.00 and gave the stock a “strong-buy” rating in a report on Friday. Zacks Investment Research lowered shares of AngioDynamics from a “buy” rating to a “hold” rating and set a $15.00 price target on the stock. in a research report on Tuesday, December 1st. BidaskClub raised AngioDynamics from a “hold” rating to a “buy” rating in a research note on Wednesday. Finally, Canaccord Genuity upped their target price on AngioDynamics from $14.00 to $18.00 and gave the stock a “hold” rating in a research report on Friday. Two investment analysts have rated the stock with a hold rating, two have given a buy rating and one has issued a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and an average price target of $19.00.

AngioDynamics Company Profile

AngioDynamics, Inc designs, manufactures, and sells various medical, surgical, and diagnostic devices for the treatment of peripheral vascular disease and vascular access; and for use in oncology and surgical settings in the United States and internationally. The company provides NanoKnife ablation systems for the surgical ablation of soft tissues; solero microwave tissue ablation systems; and radiofrequency ablation products for ablating solid cancerous or benign tumors.

Read More: Certificate of Deposit (CD)

Earnings History for AngioDynamics (NASDAQ:ANGO)

Receive News & Ratings for AngioDynamics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AngioDynamics and related companies with's FREE daily email newsletter.